PE20070603A1 - COMPOSICION FARMACEUTICA QUE COMPRENDE UN INHIBIDOR DE ESCUALENO SINTASA Y UN INHIBIDOR DE 3-HIDROXI-3-METILGLUTARIL-CoA-REDUCTASA (HMG-CoA) - Google Patents
COMPOSICION FARMACEUTICA QUE COMPRENDE UN INHIBIDOR DE ESCUALENO SINTASA Y UN INHIBIDOR DE 3-HIDROXI-3-METILGLUTARIL-CoA-REDUCTASA (HMG-CoA)Info
- Publication number
- PE20070603A1 PE20070603A1 PE2006000566A PE2006000566A PE20070603A1 PE 20070603 A1 PE20070603 A1 PE 20070603A1 PE 2006000566 A PE2006000566 A PE 2006000566A PE 2006000566 A PE2006000566 A PE 2006000566A PE 20070603 A1 PE20070603 A1 PE 20070603A1
- Authority
- PE
- Peru
- Prior art keywords
- inhibitor
- coa
- hmg
- reductase
- hydroxy
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 4
- CABVTRNMFUVUDM-VRHQGPGLSA-N (3S)-3-hydroxy-3-methylglutaryl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C[C@@](O)(CC(O)=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 CABVTRNMFUVUDM-VRHQGPGLSA-N 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 102000004286 Hydroxymethylglutaryl CoA Reductases Human genes 0.000 title 2
- 108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 title 2
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 abstract 3
- -1 CARBOXYL Chemical class 0.000 abstract 2
- KKFDJZZADQONDE-UHFFFAOYSA-N (hydridonitrato)hydroxidocarbon(.) Chemical class O[C]=N KKFDJZZADQONDE-UHFFFAOYSA-N 0.000 abstract 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 abstract 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 108010022535 Farnesyl-Diphosphate Farnesyltransferase Proteins 0.000 abstract 1
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 abstract 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 abstract 1
- 102100037997 Squalene synthase Human genes 0.000 abstract 1
- TUCNEACPLKLKNU-UHFFFAOYSA-N acetyl Chemical compound C[C]=O TUCNEACPLKLKNU-UHFFFAOYSA-N 0.000 abstract 1
- 229960005370 atorvastatin Drugs 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 150000002430 hydrocarbons Chemical group 0.000 abstract 1
- 229960004844 lovastatin Drugs 0.000 abstract 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 abstract 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229960002855 simvastatin Drugs 0.000 abstract 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE: A) UN INHIBIDOR DE ESCUALENO SINTASA DE FORMULA (I) DONDE R1 ES H O UN GRUPO HIDROCARBURO; R2 Y R3 SON CADA UNO H, HETEROCICLICO OPCIONALMENTE SUSTITUIDO, ENTRE OTROS; X' ES CARBOXILO, CARBAMOILO, OH, NH, ENTRE OTROS; A ES BENCENO O HETEROCICLICO OPCIONALMENTE SUSTITUIDO; J' ES UN ANILLO HETEROCICLICO DE 7 O 8 MIEMBROS; SIENDO UN COMPUESTO PREFERIDO EL ACIDO N-[[(3R,5S)-1-(3-ACETOXI-2,2-DIMETILPROPIL)-7-CLORO-5-(2,3-DIMETOXIFENIL)-2-OXO-1,2,3,5-TETRAHIDRO-4,1-BENZOXAZEPIN-3-IL]ACETIL]PIPERIDIN-4-ACETICO; Y B) UN INHIBIDOR DE LA ENZIMA 3-HIDROXI-3-METILGLUTARIL COENZIMA A (HMG-CoA) REDUCTASA TAL COMO ATORVASTATINA, LOVASTATINA, SIMVASTATINA, ENTRE OTROS. DICHA COMPOSICION ES UTIL PARA EL TRATAMIENTO DE HIPERLIPIDEMIA
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US68587105P | 2005-06-01 | 2005-06-01 | |
| US72832905P | 2005-10-20 | 2005-10-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20070603A1 true PE20070603A1 (es) | 2007-06-22 |
Family
ID=36699172
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2006000566A PE20070603A1 (es) | 2005-06-01 | 2006-05-31 | COMPOSICION FARMACEUTICA QUE COMPRENDE UN INHIBIDOR DE ESCUALENO SINTASA Y UN INHIBIDOR DE 3-HIDROXI-3-METILGLUTARIL-CoA-REDUCTASA (HMG-CoA) |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20090209510A1 (es) |
| EP (1) | EP1962832A2 (es) |
| JP (1) | JP2008542191A (es) |
| KR (1) | KR20080012916A (es) |
| AR (1) | AR054368A1 (es) |
| AU (1) | AU2006253255A1 (es) |
| BR (1) | BRPI0610484A2 (es) |
| CA (1) | CA2609784A1 (es) |
| CR (1) | CR9521A (es) |
| IL (1) | IL187207A0 (es) |
| MA (1) | MA29531B1 (es) |
| MX (1) | MX2007014730A (es) |
| NO (1) | NO20076566L (es) |
| PE (1) | PE20070603A1 (es) |
| RU (1) | RU2007149337A (es) |
| TW (1) | TW200714280A (es) |
| WO (1) | WO2006129859A2 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI407955B (zh) | 2007-03-29 | 2013-09-11 | Kowa Co | 高脂血症之預防及／或治療劑 |
| CA2711814A1 (en) * | 2008-01-10 | 2009-07-16 | Takeda Pharmaceutical Company Limited | Capsule formulation |
| CN103502820B (zh) | 2011-04-08 | 2016-09-07 | 佐拉生物科学公司 | 用于他汀引发的肌肉毒性的灵敏检测的生物标志物 |
| US9541565B2 (en) | 2011-04-08 | 2017-01-10 | Zora Biosciences Oy | Biomarkers for sensitive detection of statin-induced muscle toxicity |
| RU2543485C2 (ru) * | 2013-02-26 | 2015-03-10 | Андрей Александрович Иващенко | Гетероциклические агонисты рецепторов желчных кислот tgr5, фармацевтическая композиция, способы их получения и применения |
| US11833133B2 (en) | 2020-08-13 | 2023-12-05 | Orient Pharma Co., Ltd. | Solid oral pharmaceutical composition |
| TWI760067B (zh) * | 2020-08-13 | 2022-04-01 | 友霖生技醫藥股份有限公司 | 固態口服醫藥組成物 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4929437A (en) * | 1989-02-02 | 1990-05-29 | Merck & Co., Inc. | Coenzyme Q10 with HMG-CoA reductase inhibitors |
| CA2007643A1 (en) * | 1989-02-01 | 1990-08-01 | Donald S. Karanewsky | Combination of an hmg coa reductase inhibitor and a squalene synthetase inhibitor and method for lowering serum cholesterol using such combination |
| WO1994007485A1 (en) * | 1992-10-06 | 1994-04-14 | Merck & Co., Inc. | Zaragozic acid derivatives and methods of treating hypercholesterolemia, fungal growth, and cancer therewith |
| RU2040932C1 (ru) * | 1993-12-17 | 1995-08-09 | Крестьянское хозяйство "Агрофирма Дижа" | Препарат, влияющий на тканевой обмен и применение штамма гриба fusarium sambucinum fuckel var ossicolum (berk.et curf) bilai для его получения |
| JP3479796B2 (ja) * | 1995-09-13 | 2003-12-15 | 武田薬品工業株式会社 | ベンゾオキサゼピン化合物 |
| EP0862562B1 (en) * | 1995-09-13 | 2001-07-04 | Takeda Chemical Industries, Ltd. | Benzoxazepine compounds, their production and use as lipid lowering agents |
| US6537987B1 (en) * | 1996-06-20 | 2003-03-25 | Pfizer Inc. | 4,1-benzoxazepines or 4,1-benzothiazepines and their use as squalene synthetase inhibitors |
| WO2001098282A1 (en) * | 2000-06-23 | 2001-12-27 | Takeda Chemical Industries, Ltd | Benzoxazepinones and their use as squalene synthase inhibitors |
| KR20030048465A (ko) * | 2000-11-09 | 2003-06-19 | 다케다 야쿠힌 고교 가부시키가이샤 | 고밀도 지질단백질-콜레스테롤 상승제 |
| EP1249230B1 (de) * | 2001-04-12 | 2003-11-05 | Vesifact Ag | Coenzym Q10 enthaltende Mikroemulsion-Prekonzentrate und Mikroemulsionen |
| EP1407782A4 (en) * | 2001-06-28 | 2004-10-20 | Takeda Chemical Industries Ltd | AGENTS FOR PREVENTION / TREATMENT OF FUNCTIONAL ORGANIC DISEASES AND ORGANIC DYSFUNCTION |
| EP1600166A4 (en) * | 2003-01-17 | 2008-02-27 | Takeda Pharmaceutical | SKELETAL MUSCLE PROTECTIVE AGENT |
-
2006
- 2006-05-30 AR ARP060102234A patent/AR054368A1/es not_active Application Discontinuation
- 2006-05-30 TW TW095119105A patent/TW200714280A/zh unknown
- 2006-05-31 PE PE2006000566A patent/PE20070603A1/es not_active Application Discontinuation
- 2006-05-31 EP EP06747198A patent/EP1962832A2/en not_active Withdrawn
- 2006-05-31 RU RU2007149337/14A patent/RU2007149337A/ru not_active Application Discontinuation
- 2006-05-31 AU AU2006253255A patent/AU2006253255A1/en not_active Abandoned
- 2006-05-31 KR KR1020077027881A patent/KR20080012916A/ko not_active Withdrawn
- 2006-05-31 JP JP2007555360A patent/JP2008542191A/ja not_active Withdrawn
- 2006-05-31 US US11/921,422 patent/US20090209510A1/en not_active Abandoned
- 2006-05-31 CA CA002609784A patent/CA2609784A1/en not_active Abandoned
- 2006-05-31 BR BRPI0610484A patent/BRPI0610484A2/pt not_active IP Right Cessation
- 2006-05-31 MX MX2007014730A patent/MX2007014730A/es not_active Application Discontinuation
- 2006-05-31 WO PCT/JP2006/311362 patent/WO2006129859A2/en not_active Ceased
-
2007
- 2007-11-06 IL IL187207A patent/IL187207A0/en unknown
- 2007-11-15 CR CR9521A patent/CR9521A/es not_active Application Discontinuation
- 2007-12-03 MA MA30449A patent/MA29531B1/fr unknown
- 2007-12-19 NO NO20076566A patent/NO20076566L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| MX2007014730A (es) | 2008-02-15 |
| AU2006253255A1 (en) | 2006-12-07 |
| CR9521A (es) | 2008-02-22 |
| EP1962832A2 (en) | 2008-09-03 |
| BRPI0610484A2 (pt) | 2017-01-31 |
| TW200714280A (en) | 2007-04-16 |
| WO2006129859A3 (en) | 2007-04-19 |
| AR054368A1 (es) | 2007-06-20 |
| JP2008542191A (ja) | 2008-11-27 |
| WO2006129859A2 (en) | 2006-12-07 |
| RU2007149337A (ru) | 2009-07-10 |
| CA2609784A1 (en) | 2006-12-07 |
| NO20076566L (no) | 2008-02-22 |
| IL187207A0 (en) | 2008-06-05 |
| KR20080012916A (ko) | 2008-02-12 |
| MA29531B1 (fr) | 2008-06-02 |
| US20090209510A1 (en) | 2009-08-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20110367A1 (es) | DERIVADOS DE 4-CIANO-4-FENIL-PIRROLIDIN-2-CARBOXAMIDAS SUSTITUIDAS COMO INHIBIDORES DE LA INTERACCION p53-MDM2 | |
| EA200700185A1 (ru) | Производные хиназолиндиона в качестве ингибиторов parp | |
| EA200500203A1 (ru) | Новый способ синтеза и новая кристаллическая форма агомелатина и фармацевтические композиции, которые её содержат | |
| PE20011294A1 (es) | Composiciones farmaceuticas de agonistas/antagonistas de estrogeno y estatinas para tratar la osteoporosis y reducir el colesterol | |
| EA200800727A1 (ru) | Введение ингибиторов дипептидилпептидазы | |
| EA201000958A1 (ru) | Пептидилнитрилы и их применение в качестве ингибиторов дипептидилпептидазы i | |
| EA201001680A1 (ru) | Соединения бензолсульфонамидтиазола и оксазола | |
| BRPI0408353A (pt) | composto, composição farmacêutica, métodos para o tratamento de neoplasias suscetìveis e para o tratamento de infecções virais, e, uso de um composto | |
| MA31763B1 (fr) | Inhibiteurs de kinase de type polo | |
| BR0308613A (pt) | Combinação de compostos orgânicos | |
| MY150941A (en) | Benzazepine derivatives useful as vasopressin antagonists | |
| MX2009006481A (es) | Derivados de imidazol 1-sustituidos, y su uso como inhibidores de la sintasa de aldosterona. | |
| WO2012002741A3 (en) | Process for the preparation of hmg-coa reductase inhibitors and intermediates thereof | |
| EA200701822A1 (ru) | Пиразолилкарбоксанилиды | |
| AR039399A1 (es) | Compuestos quimicos con actividad doble, procedimientos para su preparacion y composiciones farmaceuticas | |
| MA32929B1 (fr) | Lactames en tant qu'inhibiteurs de bêta-sécrétase | |
| PE20100144A1 (es) | Compuestos quimicos 293 | |
| MA33945B1 (fr) | Procédés de fabrication d'un principe pharmaceutiquement actif | |
| AR054481A1 (es) | Derivados de 2-azetidinonas como inhibidores de la absorcion de colesterol | |
| AR057072A1 (es) | Compuestos quimicos derivados de 2-azetidinona, formulacion farmaceutica y un proceso de preparacion del compuesto | |
| PE20070603A1 (es) | COMPOSICION FARMACEUTICA QUE COMPRENDE UN INHIBIDOR DE ESCUALENO SINTASA Y UN INHIBIDOR DE 3-HIDROXI-3-METILGLUTARIL-CoA-REDUCTASA (HMG-CoA) | |
| BR112012009861A2 (pt) | composto, composição farmacêutica, e, uso do composto. | |
| EA201200868A1 (ru) | Ингибиторы диацилглицеролацилтрансферазы | |
| AR059031A1 (es) | Combinacion de derivados de triazina e inhibidores de la hmg- coa reductasa | |
| PE20050050A1 (es) | Derivados de indolilo |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |